Health
Hope grows for blood cancer patients, as cell therapy firm’s key trial succeeds – The Times of Israel
Gamida Cell shares surge after results of key trial show flagship drug results in faster blood count recovery, fewer bacterial and viral infections after bone marrow…
Gamida Cell Ltd., a maker of cell and immune therapy technologies, on Wednesday published the results of a key late-stage clinical trial of its flagship drug, which aims to increase the success of bone marrow transplants in blood cancer patients — triggering a surge in its Nasdaq-traded shares.
Gamida’s shares jumped almost 26% on the US exchange Wednesday. The shares have advanced 163% in the past 12 months, leading to a company valuation of $733 million. The firm held its initial public offering…
-
Noosa News23 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs
-
Business14 hours ago10 ASX shares to buy after the market selloff
-
General17 hours ago‘We are here for you’: PM to bring help to flood zones
-
General16 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening